论文部分内容阅读
异基因骨髓移植(BMT)是慢性粒细胞白血病(CML)重症再生障碍性贫血、地中海贫血和一些少见疾病的治疗选择。虽然自体骨髓移植对首次缓解的急性白血病和某些实体瘤也同时取得了不同程度的成功。但通过异基因细胞介导的移植物抗白血病反应(GVL)起着重要作用。因而,如果与异基因移植相关的疾病发病率和死亡率能有所改善,异基因BMT比自体BMT更可取。在英国平均有3个孩子的家庭发现一个组织配型完全相同的同胞的机率为0.3,在中国这样大多数家庭只有一个孩子的国家,这种机率为零。
Allogeneic bone marrow transplantation (BMT) is a treatment option for chronic myeloid leukemia (CML), severe aplastic anemia, thalassemia and some rare diseases. Although autologous bone marrow transplantation for the first time to alleviate the acute leukemia and some solid tumors also achieved varying degrees of success. But plays an important role through allogeneic cell-mediated graft versus leukemia response (GVL). Thus, allogeneic BMT is preferable to autologous BMT if morbidity and mortality from diseases associated with allogeneic transplantation can be improved. A family with an average of three children in the UK found a 0.3 probability of having a matching sibling of the same organization. In China, where most families have only one child, the odds are zero.